<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097106</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #19-601</org_study_id>
    <nct_id>NCT04097106</nct_id>
  </id_info>
  <brief_title>Synbiotic Dietary Supplement and Gut Microbiota</brief_title>
  <official_title>Synbiotic Supplement Effects on Gastrointestinal Symptoms and Gut Microbiota and Fecal Metabolomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the feasibility and safety of our designer synbiotic on gastrointestinal symptoms and
      gut microbiota and fecal metabolomics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure change in gastrointestinal symptoms using &quot;Rating of Gastrointestinal (GI) Symptoms&quot; scale</measure>
    <time_frame>Baseline, Day 28, day 49, day 77</time_frame>
    <description>Rating of GI Symptoms scale includes 5 questions, which range from 0 (never affected) to 7 (always bothered), summed to compute total score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in microbiome stool diversity</measure>
    <time_frame>Baseline, Day 28, day 49, day 77</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in metabolome stool profile</measure>
    <time_frame>Baseline, Day 28, day 49, day 77</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in metabolome urine profile</measure>
    <time_frame>Baseline, Day 28, day 49, day 77</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lean BMI (19-25)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese BMI (30-35)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>Synbiotic dietary supplement in capsule form</description>
    <arm_group_label>Lean BMI (19-25)</arm_group_label>
    <arm_group_label>Obese BMI (30-35)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Thirty two healthy volunteers, aged 18-45 years old, will be recruited for this pilot
        study, plan to enroll 16 subjects with a BMI 19-25 kg/m2 and 16 subjects with a BMI 30-35
        kg/m2.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 19-25 (lean) and BMI 30-35 (obese)

          -  Age 18-45 years old

          -  subjects must be willing to consume oral dietary supplement and placebo daily for a
             total of 56 days,

          -  willing to complete gastrointestinal (GI) and dietary surveys, body composition
             assessment, and provide blood, urine and stool sample at 4 intervals during the pilot
             study (baseline, after first supplementation period (day 28), after washout period
             (day 49), and after second supplementation period (day 77)

        Exclusion Criteria:

          -  antibiotic consumption within 28 days of study initiation

          -  diabetes

          -  kidney disorders

          -  history of cardiac disease and medications for cardiac disease

          -  use of statins and antihypertensive drugs

          -  inflammatory bowel disease

          -  irritable bowel syndrome

          -  history of small intestinal bacterial overgrowth

          -  history of intestinal surgery, excluding hernia repair and appendectomy

          -  active cancer diagnosis; chronic acid suppression treatment (proton pump inhibitors,
             histamine H2 receptor antagonists)

          -  immune modulatory treatments (e.g. chronic immunosuppressive medications, chronic
             NSAIDs)

          -  abnormal liver or kidney function as measured by routine serum chemistry testing

          -  severe anemia or significant white blood cell or platelet abnormalities

          -  no additional blood or blood product donations during study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Wojanowski</last_name>
    <phone>216-445-2282</phone>
    <email>wojanoh@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Heather Wojanowski</last_name>
      <phone>216-445-2282</phone>
      <email>wojanoh@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Gail Cresci, PhD, RD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Gail Cresci</investigator_full_name>
    <investigator_title>Director Nutrition Research within Center for Human Nutrition</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

